AMSTERDAM, THE NETHERLANDS -- (MARKET WIRE) -- 07/31/08 -- Following the approval by theExtraordinary General Meeting of Shareholders on 30 May 2008 to delaypublication of the 2007 Annual Report, OctoPlus N.V. (Euronext: OCTO)announces today that it will also postpone publication of its results forthe first 6 months of 2008, previously scheduled for August 1, until afterthe 2007 Annual Report is published.About OctoPlus
OctoPlus N.V. is a product-oriented biopharmaceutical company committed tothe creation of improved pharmaceutical products that are based onOctoPlus' proprietary drug delivery technologies and have fewer sideeffects, improved patient convenience and a better efficacy/safety balancethan existing therapies. Rather than seeking to discover novel drugcandidates through early stage research activities, OctoPlus focuses on thedevelopment of long-acting, controlled-release versions of known proteintherapeutics, other drugs, and vaccines.
Our pipeline consists of 5 products in pre-clinical and clinicaldevelopment. Our lead product is Locteron, a controlled release formulationof interferon alfa for the treatment of chronic hepatitis C, which we areco-developing with Biolex Therapeutics. Locteron is currently in Phase IIclinical studies. Furthermore, our pipeline comprises a product candidatefor the treatment of chronic middle ear infection, which has completedPhase II clinical proof of concept testing, a pre-clinical GLP-1 analogueproduct candidate for the treatment of diabetes and two pre-clinical-stagesingle-shot vaccines.
In addition, OctoPlus is a European leading provider of advanced drugformulation and clinical scale manufacturing services to the pharmaceuticaland biotechnology industries, with a focus on difficult to formulate activepharmaceutical ingredients. The earnings and expertise that we derive fromrendering formulation and manufacturing services help to support our owndrug development programs.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbolOCTO. For more information about OctoPlus, please visit our websitewww.octoplus.nl.
This document may contain certain forward-looking statements relating tothe business, financial performance and results of OctoPlus N.V. and theindustry in which it operates. These statements are based on OctoPlusN.V.'s current plans, estimates and projections, as well as itsexpectations of external conditions and events. In particular the words"expect", "anticipate", "predict", "estimate", "project", "plan", "may","should", "would", "will", "intend", "believe" and similar expressions areintended to identify forward-looking statements. We caution investors thata number of important factors, and the inherent risks and uncertaintiesthat such statements involve, could cause actual results or outcomes todiffer materially from those expressed in any forward-looking statements.In the event of any inconsistency between an English version and a Dutchversion of this document, the English version will prevail over the Dutchversion.
Press release in PDF: http://hugin.info/137076/R/1239330/265403.pdf
For further information, please contact:
Rianne Roukema
Corporate Communications
telephone number +31 (71) 524 1071
or e-mail IR@octoplus.nl.
